The Latest in Stroke Risk Reduction Strategies: Are Your Patients Protected?

Learn about the role GLP-1 RAs play in stroke risk reduction, especially among patients with type 2 diabetes. Expert faculty review the latest evidence and strategies for individualizing care plans to address patients’ stroke risk through ClinicalThought commentaries, an on-demand webcast with accompanying slides, and a downloadable clinical resource.

Share

Program Content

Events

Activities

Stroke Risk Reduction
The Latest in Stroke Risk Reduction Strategies: Are Your Patients Protected?
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 27, 2024

Expires: September 26, 2025

Activities

Stroke Risk Reduction in Diabetes Care
Stroke Risk Reduction and Outcomes With Novel Therapies in Diabetes Care
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 26, 2024

Expires: August 25, 2025

Activities

GLP-1 RAs for T2D
Quick Guide to GLP-1 RA and GIP/GLP-1 Coagonists for T2D Care
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: September 27, 2024

Expires: September 26, 2025

Faculty

cover img faculity

Richard E. Pratley, MD

AdventHealth Samuel E. Crockett Chair in Diabetes Research
Medical Director, Advent Health Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins School of Medicine
Orlando, Florida

cover img faculity

Alejandro A. Rabinstein, MD, FAHA

Professor of Neurology
Chair, Hospital Neurology and Neurocritical Care Division
Mayo Clinic
Rochester, Minnesota

cover img faculity

Jay H. Shubrook, DO, FACOFP, FAAFP

Professor and Diabetologist
Department of Clinical Sciences and Community Health
Touro University California
College of Osteopathic Medicine
Vallejo, California

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk